David Shulman
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Shulman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:22 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06709495 · Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDavid S Shulman, MD · recruiting · Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor · principal investigator
- Ph2NCT04129151 · Palbociclib + Ganitumab In Ewing SarcomaDana-Farber Cancer Institute · terminated · Ewing Sarcoma, Ewing's Sarcoma Recurrent · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Validation and implementation of ctDNA as a clinically informative biomarkerin AYAs with sarcomas.K08CA290061 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $253,592 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:22 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.J Clin Endocrinol Metab · 200777 citationsRCR 2.3
- A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.Am J Ophthalmol · 199768 citationsRCR 3.5
- Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.Pediatr Diabetes · 202253 citationsRCR 4.8
- A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.Ophthalmology · 199949 citationsRCR 2.3
- Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome.J Clin Endocrinol Metab · 200748 citationsRCR 1.6
- Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency.J Clin Endocrinol Metab · 200340 citationsRCR 1.0
- Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.Cancer Med · 202336 citationsRCR 3.3
- Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.Am J Ophthalmol · 199928 citationsRCR 1.4
- Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.Diabetes Technol Ther · 202324 citationsRCR 2.8
- Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.Diabetes Technol Ther · 202323 citationsRCR 2.9